Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lodapolimab (LY3300054) alone or in combination in advanced solid tumors
NCT02791334Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of lodapolimab in solid tumor (advanced stage), cutaneous melanoma (CM), pancreatic cancer (PC) and 2 more (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities. Started Jun 2016; status: completed.
02
Drugs
lodapolimab
03
Conditions
solid tumor (advanced stage)cutaneous melanoma (CM)pancreatic cancer (PC)Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+)solid tumor
Beyond the preview
Go deeper on NCT02791334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791334.